Evaluation of echocardiographic findings of fabry patients: A single center experience

Aim: Fabry disease is a lysosomal storage disease caused by α-galactosidase A enzyme deficiency due to mutation in the GLAgene with X-linked transition. Fabry disease may present with skin, eye, kidney, cardiac and neurological system involvement.Cardiovascular findings are important in terms of mortality due to differences in clinical presentation and difficulties in diagnosis.Cardiac involvement is the most common cause of mortality, therefore echocardiographic evaluation is important at baseline.Echocardiographic examination is a noninvasive and effective diagnostic method for the evaluation of cardiac involvement duringboth diagnosis and follow-up.Material and Methods: Echocardiographic findings of 18 patients who were followed up in the outpatient clinic for Fabry diseasebetween August 2018 and December 2019 were retrospectively evaluated. All patients were evaluated for cardiac involvement by2-dimensional echocardiography.Results: Between August 2018 and December 2019, there were 18 Fabry patients who were followed up in our hospital. In ourstudy, 13 patients were female and 5 were male. The mean age was 42.2 ± 13.5 years. 12 patients with enzyme replacementtherapy had different system involvement; Seven had cardiac involvement by echocardiography. The cardiac involvement rate ofour symptomatic patients receiving treatment was 58.3% (7/12). Seven patients with cardiac involvement; Six (85.7%) had nonobstructive hypertrophic cardiomyopathy and stage 1 diastolic dysfunction in the left ventricle.Conclusion: In Fabry disease, cardiovascular findings are the most important cause of mortality and early diagnosis is important.The most common echocardiographic findings in our patient group were non-obstructive hypertrophic cardiomyopathy (85.7%)and left ventricular diastolic dysfunction. In the presence of unexplained non-obstructive hypertrophic cardiomyopathy, Fabrydisease should be considered in the differential diagnosis. Fabry disease have multisystemic involvement, it requires absolutemultidisciplinary approach in the diagnosis and follow-up of patients.

PDF

___

1. Clarke JTR. Narrative review: Fabry disease. Ann Intern Med 2007;146:425-33.
2. Putko BN, Wen K, Thompson RB, et al. AndersonFabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev 2015;20:179- 91.
3. Yuasa T, Takenaka T, Higuchi K, et al. Fabry disease. J Echocardiogr 2017;15:151-7.
4. Yeung DF, Sirrs S, Tsang MYC, et al. Echocardiographic Assessment of Patients with Fabry Disease. J Am Soc Echocardiogr 2018;31:639-49.
5. Wu JC, Ho CY, Skali H, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010;31:1088-97.
6. Morrissey RP, Philip KJ, Schwarz ER. Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy. Cardiovasc J Afr 2011;22:38-44.
7. Kim W-S, Kim HS, Shin J, et al. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy. J Korean Med Sci 2019;34:63.
8. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
9. Terryn W, Deschoenmakere G, De Keyser J, et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol 2013;167:2555-60.
10. Barman HA, Ikitimur B, Kilickiran Avci B, et al. The Prevalence of Fabry Disease Among Turkish Patients with Non-obstructive Hypertrophic Cardiomyopathy: Insights from a Screening Study. Balkan Med J 2019; 36:354-8.
11. Niemann M, Liu D, Hu K, et al. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol 2011;37:37-43.
12. Kayıkçıoğlu M, Şimşek E, Kalkan Uçar S, et al. Fabry disease: An overlooked diagnosis in adult cardiac patients. Turk Kardiyol Dern Ars 2017;45:549-55.
13. Mehta A, Clarke JTR, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
14. Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol Genet Metab Rep 2015;3:21-7.
15. Seo J, Kim M, Hong G-R, et al. Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis. J Hum Genet 2016;61:775-80.
16. Hagège A, Réant P, Habib G, et al. Fabry disease in cardiology practice: Literature review and expert point of view. Arch Cardiovasc Dis 2019;112:278-287.